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Chryseobacterium meningosepticum is a ubiquitous Gram-negative bacillus historically associated primarily with meningitis in
neonates and a wide variety of infections in immunocompromised patients. Neonatal infections often occur as outbreaks with
environmental contamination being the source. C. meningosepticum infections are not common but are clinically important
because the organism is naturally resistant to multiple antibiotics. In this paper, we have reviewed the nosocomial outbreaks of
C. meningosepticum in newborns and infants reported so far in the literature and overviewed the infection control interventions,
treatment modalities, and prevention measures.
1.Introduction
Chryseobacteriummeningosepticumisanonfermenting,non-
motile, oxidase-positive Gram-negative aerobic bacillus that
is ubiquitous in the environment, found in freshwater,
saltwater, and soil. It was ﬁrst deﬁned by King in 1959
[1]. King also used serological procedures for typing strains
isolated in epidemiological studies, and 6 serotypes (A to F)
havebeendescribed,typeCbeingresponsibleformostofthe
cases of meningitis [1]. This ubiquitous bacterium, formerly
known as Flavobacterium meningosepticum and recently
termed Elizabethkingia meningosepticum (or meningoseptica)
by some authors, belongs to the family of Flavobacteriae and
inhabits natural and hospital environments [2–5].
Environmental studies have revealed that the organism
can survive in chlorine-treated municipal water supplies,
often colonises sink basins and taps, and has become a
potential reservoir for infections in the hospital environment
[6, 7]. Colonization of patients via contaminated medical
devices involving ﬂuids (respirators, intubation tubes, mist
tents, humidiﬁers, incubators for newborns, ice chests,
syringes, etc.) has been documented [8, 9]. Contaminated
surgically implanted devices such as intravascular catheters
and prosthetic valves have also been reported as reservoirs
[10].
2. ClinicalPresentation
In clinical settings, Chryseobacteria have been described as
etiological agents of meningitis, sepsis, bacteremia, pneumo-
nia, endocarditis, infections of skin and soft tissue, wound
infection, abdominal abscess, ocular infections, sinusitis,
bronchitis, epididymitis, dialysis-associated peritonitis, and
prosthesis-associated septic arthritis [6, 11–13]. As primarily
opportunistic pathogens, they infect mainly newborns and
immunocompromised hosts from all age groups [6].
Among the Chryseobacterium species, C. meningosepti-
cum is the most pathogenic member of genus. C. meningo-
septicum is a cause of neonatal meningitis, especially in pre-
mature infants during the ﬁrst weeks of life. In newborns,
meningitis is the most common disease caused by this
orga-nism. Bacteremia and pneumonia are the other com-
mon manifestations in neonates. Infections usually aﬀect
premature infants and often occur as outbreaks [9, 14].
Prematurity is a primary risk factor for C. meningosepticum
infection, and half of the infections have involved neonates
weighing less than 2,500g [9]. Among the various serotypes
of C. meningosepticum (A to F), type C has been the cause
of most reported epidemics [3, 15]. As an agent of neonatal
meningitis, it reportedly demonstrates mortality rates up to
57% and produces severe postinfectious sequelae including2 International Journal of Pediatrics
brain abscesses, hydrocephalus, deafness, and developmental
delay. The case-fatality rate has been high in neonates, and
early and late complications are common among survivors
[11, 15–17]. C. meningosepticum is involved to a lesser extent
in cases of pneumonia and bacterial sepsis in neonates and
adults [6].
Bacteremia is the second most common presentation of
C. meningosepticum infection. C. meningosepticum has also
caused endocarditis (including prosthetic valves), cellulitis,
wound infections, sepsis following extensive burns, abdom-
inal abscess, dialysis-associated peritonitis, and endoph-
thalmitis.Infectionsincludingcellulitis,septicarthritis,com-
munity-acquired respiratory tract infection, keratitis, and
bacteremia have been reported in the absence of underlying
diseases [18].
3. Transmission and Sources of the Infection
Neonatal infections due to C. meningosepticum could be
through vertical transmission; however, no data about this
kind of transmission of the organism is available. As
many interventions (endotracheal intubation, central and
peripheral intravascular catheterization, etc.) are made in
the neonatal intensive care units (NICUs) and majority of
the C. meningosepticum infections reported have been in
NICUs, the infections of these neonates are often considered
as nosocomial.
Clustersofneonatalmeningitis havebeenlinked tomany
sources including contaminated saline solution for ﬂushing
eyes,respiratoryequipment,andsinkdrains.Therespiratory
tract is the most common site of infection, and outbreaks
have been linked to contaminated ventilator tubing and
aerosols. In outbreaks, respiratory tract colonization occurs
more often than infection [6]. Other contaminated sources
includecontaminatedsyringesinicechests,vials,sinkdrains,
sink taps, tube feedings, ﬂush solutions for arterial catheters,
pressure transducers, and antiseptic solutions [18].
Cabrera and Davis [19]r e p o r t e da no u t b r e a ko f1 4c a s e s
of neonatal meningitis due to C. meningosepticum where the
sourcewastracedtoaleakingsinktrapinananteroomofthe
premature ward. Repair of the faulty leaky trap eradicated
the reservoir of this infection and terminated the outbreak.
Plotkin and McKitrick [20] described two cases of ﬂavobac-
terium meningitis which were traced to a saline solution.
This saline solution containing Flavobacteria was stored in a
glass bottle that was seldom sterilised but reﬁlled with sterile
saline as needed. The solution was aspirated into a rubber
bulbandusedtoﬂushtheeyesofinfantsaftertheapplication
of silver nitrate solution. Coyle-Gilchrist et al. [21] isolated
C. meningosepticum from aqueous chlorhexidine gluconate
(Hibitane) solutions used in the wards for the storage of
thermometers and for routine disinfection. The two separate
C.meningosepticumtypeEoutbreaksarereportedbyHazuka
et al. [15] in the NICU, The organism was ﬁrst isolated
from nasoendotracheal (NET) tube cultures in four of
eight infants who were intubated. C. meningosepticum was
recovered from three nasoendotracheal tubes and from an
aerosol tube before colonization of four infants. In the
outbreaks, we reported that C. meningosepticum was isolated
from hand cultures obtained from a senior resident and
fromenvironmentalculturesobtained frompowderedinfant
formula, an electrical button, a computer keyboard, phone, a
doorknob, and an ambu bag.
4. Infection and Colonization
When the organism is colonized in a susceptible individual
(e.g., in the respiratory tract), no clinical signs or symptoms
areobserved,butthispersonhasthepotentialtoinfectothers
unless necessary precautions are taken. Under usual condi-
tions, colonized individuals are not given any antibacterial
therapy. If this colonization progresses to clinical infection—
demonstrates the signs and symptoms of infection—or the
colonized individual infects another susceptible individual
and causes infection, then “the infection” should be treated
with appropriate antibacterial therapy.
Susceptible patients may become colonized after acquir-
ing the organism from the healthcare worker, and infection
may or may not ensue [19]. During the outbreak on a
NICU, two neonates were infected (one had pneumonia
and one septicaemia and meningitis), and six neonates were
colonized in the respiratory secretions by a multiresistant C.
meningosepticum. Two of the eight patients had infection,
the others were colonized (in tracheal aspirate, sputum, or
perineum) and needed no antibiotic therapy [19]. However,
not all neonates exposed to the organism became ill. Cabrera
and Galen reported that only one twin of each of three sets
became ill and died, while the other twins neither became
ill nor were colonised by this organism. This suggests that
immune mechanisms may play a role in these nosocomial
infections [19].
Maraki et al. [22] reported four neonates with C. meni-
ngosepticum colonization in the endotracheal tubes and
respiratory secretions in an NICU. None of the neonates
progressed to clinical infection, and none of them received
speciﬁc treatment and all survived. This study suggested
that C. meningosepticum colonization in neonates does not
necessarily lead to infection and that such colonization out-
breaks may be controlled with emphasis on the standard pre-
cautions [22]. If the clinical signs and symptoms can not be
evaluated properly, colonization and infection may not be
discriminated.
5. Hospital Infections
Since ﬁrst recognition of C. meningosepticum as a cause of
neonatal meningitis in 1958, outbreaks have occasionally
been described since 1961 [23–28].
Brody et al. [23] described two outbreaks of meningitis
caused by C. meningosepticum aﬀecting primarily premature
infants in a hospital nursery. This outbreak was described
as hospital acquired, but attempts to isolate the organism
from human contacts were unsuccessful. Cabrera and Galen
[19] reported an outbreak of 14 cases of neonatal meningitis,
George et al. [29] reported 14 cases of meningitis and 30
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intheirnewbornward.PlotkinandMcKitrick[30]described
two cases of ﬂavobacterium meningitis which were traced to
a saline solution. We could not reach to more detailed data of
these reports in our literature search.
Between March and July 1975, two separate C. menin-
gosepticum type E outbreaks were reported by Hazuka et al.
[15] in the neonatal ˙ Intensive Care Unit at Children’s Hos-
pital of Michigan. Of the 10 infants aﬀected, only 3 in the
ﬁrst outbreak exhibited disease directly related to C. meni-
ngosepticum. The remaining two infants in March-April
and all ﬁve infants in July were colonized but not infect-
ed. The three ill infants had positive blood cultures. Two
developed meningitis; one died within 6 days, and the other
survived but developed hydrocephalus requiring a ventricu-
loperitoneal shunt. The one patient who did not develop
meningitis had only a transient bacteremia, was treated with
appropriateantibiotics,andeventuallywasdischargedhome.
The organism was resistant to most antimicrobial agents
tested and developed resistance to others during treatment
[15].
Between 1972 and 1977, Thong et al. [14]r e p o r t e ds e v e n
infants with C. meningosepticum infection. C. meningosep-
ticum was isolated from the cerebrospinal ﬂuid in all seven
infants, from blood in three infants, and from peritoneal
ﬂuid in one infant. Two cases who died did not receive intra-
ventricular chemotherapy. Five infants survived, and three
of them were normal neurologically. One of the survivors
had hydrocephalus with severe brain damage; the infection
in this infant began with umbilical sepsis and peritonitis.
Theinfectingorganismwasisolatedfromtheperitonealﬂuid
two days before the cerebrospinal ﬂuid yielded the same
organism. The other case also had hydrocephalus without
showing any other evidence of neurological handicap [14].
In 1980, Dooley et al. [30] summarized 63 previ-
ously reported cases of C. meningosepticum meningitis that
occurred from 1944 to 1976. Out of 52 infants for whom
the outcome of infection was known, 34 (65%) died. Eleven
(61%) of the 18 neonates who survived developed hydro-
cephalus [31, 32]. Overall, four (50%) of the eight neonates
whose length of gestation was known were full-term infants.
According to the available data, the mean duration that CSF
cultures remained positive was 16 days (range 8–39 days),
all of 10 infants had associated bacteremia. One death was
related to infection due to C. meningosepticum, resulting in a
case fatality rate of 8.3%. Hydrocephalus developed in 70%
of the surviving infants. Five patients received intrathecal
antibiotics [30].
Di Pentima et al. [33] isolated four strains of
C. meningosepticum from cerebrospinal ﬂuid and blood
from neonates with clinical infection between 1982 and
1996 in Texas Children’s Hospital. All of the neonates
tolerated treatment with vancomycin and rifampin well,
and no adverse eﬀects were noted. All three neonates
with meningitis due to C. meningosepticum survived
without developing hydrocephalus or neurological deﬁcits,
as determined on physical examination at the time of
discharge. Two infants developed mild sensorineural hearing
loss. C. meningosepticum was re-covered at birth in a tracheal
aspirate from the premature infant. Bacteremia due to
C. meningosepticum subsequently developed in this infant at
3 weeks of age resolved with a 10-day course of vancomycin
and ceftazidime treatment. The infant died of Staphylococcus
aureus septicemia at 2 months of age [33].
Chiu et al. [7] reported 17 culture-documented systemic
infections due to novel, atypical strains of C. meningosep-
ticum in two newborns and 15 immunocompromised
patients from 1996 to 1999 in a medical center in Taiwan. All
clinical isolates were resistant to a number of antimicrobial
agents. The isolates were characterized as atypical strains
of C. Meningosepticum, and that was the ﬁrst report of a
cluster of atypically variant strains of C. meningosepticum.
Two patients were newborns, and one was 7-year-old child
with IgA nephropathy. Three of the 15 nonneonatal patients
died of the infection; the two newborns survived with severe
neurologic sequelae, despite antibiotic treatment [7].
Hoque et al. [9] reported a strain of multiresistant
C. meningosepticum isolated from eight neonates on a
neonatal intensive care unit from September 1994 to May
1996. Two neonates were infected (one had pneumonia
and one septicaemia and meningitis); the remaining six
neonates were colonized in the respiratory secretions. Two
cases occurred that could not be explained by cross-infection
during the outbreak. The two infected neonates survived,
and the neonate with meningitis and septicaemia did not
develop hydrocephalus. Both of these infants were very low
birth weight neonates (<1500g) which is consistent with
studies that show at least 50% of neonates with this infection
weighed <2500g [9].
G¨ ung¨ or et al. [11]r e p o r t e da no u t b r e a ko fC. menin-
gosepticum in four neonates with sepsis in the NICU of a
referral teaching hospital in September 2001. The organism
was isolated from blood cultures of all four patients. The ﬁrst
isolate was identiﬁed 5 days after the death of the index case.
All three patients survived with one having a complication
(hydrocephalus) [11].
Maraki et al. [22] reported four neonates with C. men-
ingosepticum colonization in the endotracheal tubes and
respiratory secretions in an NICU of a referral teaching
hospital in Greece between April and October 2002. None
of the neonates progressed to clinical infection, and none
of them received speciﬁc treatment. This study suggested
that C. meningosepticum colonization in neonates does not
necessarily lead to infection and that such colonization
outbreaks may be controlled with emphasis on the standard
precautions [22].
Hsuetal.[34]studiedatotalof118patientswithC.men-
ingosepticum bacteremia at a medical center in Taiwan from
1999 to 2006. Among 99 preserved isolates, 84 % presented
with fever, 86% had nosocomial infections, and 60% had
acquired the infection in intensive care units (ICUs). Seventy
eight percent of patients had primary bacteremia, followed
by pneumonia (9%) and catheter-related bacteremia (6%).
Forty-ﬁve patients (38%) had poly-microbial bacteremia.
Only 6 patients were under the age of 18 and none of them
was premature, a much lower per-centage than in previous
reports [34].
We [16] reported three clusters of C. meningosepticum
infections in our hospital in July 2006 and January 20074 International Journal of Pediatrics
involving 8 newborns and 5 older children. Seven of the
newborns were premature. The index patient was from the
neonatalintensivecareunit,andtheolderpatientswerefrom
otherpediatricwards.Threeofthemhadmeningitis,twohad
primary bacteremia, ﬁve had sepsis, one had postoperative
cellulitis and fasciitis, and two had respiratory distress and
pneumonia. The organism was isolated from the blood of all,
cerebrospinal ﬂuid (CSF) of 4 of the patients. Nine patients
improved on antimicrobial treatment, and 4 premature
infantsdiedaftertheinfection.Oneoftheneonateswhodied
had meningitis, one had sepsis, and the other two had res-
piratory distress and pneumonia [16].
6. Infection Control Interventions
Outbreaks of Gram-negative bacterial infections are usually
due to transient carriage of the organisms on the hands of
healthcare workers [35]. Susceptible patients may become
colonized after acquiring the organism from the healthcare
worker, and infection may or may not develop.
Gram-negative bacteria can have an inanimate reservoir
such as hospital sinks [35, 36]. It is generally considered that
this is not an important factor in endemic hospital-acquired
infections. In those susceptible to infection, however, small
numbers of potentially pathogenic organisms present on
healthcare workers’ hands, after washing them in contami-
nated tap water, may cause infection [12, 35].
To detect the source of an outbreak of C. meningosep-
ticum, it is important to obtain cultures from food and
infant formulas, wet areas, dry surfaces, equipments, and the
hands of healthcare workers who contact with the patients.
Obtaining cultures on a periodic basis is necessary [18].
MeasuresthathavebeenusedtoeradicateC.meningosep-
ticum outbreaks in pediatric wards include changing the
prescribing policy for empiric antibiotics, restriction of
further admissions, and thorough disinfection of the unit
[9, 11, 15]. Other studies have shown successful control
with milder measures, including alcoholic hand rub after
the washing of hands, toileting of babies with sterile instead
of tap water, and repairing, cleaning, super chlorination,
isolation of the water tanks from all the hospital feeder
tanks and changing the sink taps [11, 37, 38]. Discarding
opened creams, ointments, sterile water, and hand-washing
solutions have also been among other interventions of
infectioncontrol.Strictsupervisionofthehygieneduringthe
preparation process of intravenous lipid solutions as well as
other intravenous solutions and the infant formulas is also
important as these have also been reported as important
sources of epidemics [13, 16, 18]. In our experience, we
determined that electrical buttons, computer keyboards,
phones, doorknobs, and ambu bags may also be sources
of epidemics [16]. Particularly in intensive care units, the
frequent dysinfection of these items as well as hand hygiene
can prevent epidemics. Restriction of staﬀ exchange between
wards;isolationofthepatientswithC.meningosepticumpos-
itive cultures; scrubbing units and wards thoroughly using
two disinfectants (hypochlorite solution and isopropanol
spray) with special emphasis on objects containing or in
contact with water have shown successful control [39].
In-service training should be implemented to reemphasize
handwashing and contact precautions to staﬀ.
In conclusion, surveillance for the reservoir and mainte-
nance of rigorous infection control measures are essential to
control C. meningosepticumoutbreaks in the hospital setting.
7.Resistance PatternsandMechanisms
C. meningosepticum has unusual resistance patterns and
mechanisms.Chryseobacteria areresistanttomultiple antibi-
otics, especially to β-lactams. Many possess two diﬀerent
types of β-lactamases, namely class A extended-spectrum
β-lactamases and class B metallo-β-lactamases (MBLs); the
latter confer resistance to carbapenems, which are widely
used to treat infections caused by multidrug-resistant Gram-
negative bacteria. Two types of MBL, BlaB and GOB,
have been identiﬁed in isolates of C. meningosepticum.
Although they have similar molecular weights, these two
enzyme types show only very low molecular similarity.
Sequencing and analysis of genes encoding BlaB and GOB
hasrevealedheterogeneity,withupto12blaGOBand14blaB
alleles identiﬁed [40]. C. meningosepticum is intrinsically
resistant to most β-lactams, including carbapenems, due to
production of chromosomal metallo-β-lactamases (MBLs)
[41] .B e l l a i se ta l .r e p o r t e dt h a ta l lC. meningosepticum
isolates harbored two types of MBLs simultaneously: BlaB
belonging to subclass B1 and GOB belonging to subclass B3
[42]. However, a recent survey in China reported that only
55 of 170 C. meningoseptica isolates harbored both types of
MBLs, and 38 isolates harbored only one type of MBL [43].
Furthermore, no MBL genes were detected in the remaining
77 isolates, even though many of these isolates were resistant
to imipenem. PCR experiments detected both genes encod-
ing BlaB and GOB MBLs in all C. meningosepticum isolates.
DNA sequence analysis revealed that C. meningosepticum
isolates possessed 7 types of blaB gene, including 5 novel
variants (blaB-9 to blaB-13), and 11 types of blaGOB gene,
including 10 novel variants (blaGOB-8 to blaGOB-17). The
mostcommoncombinationofMBLswasBlaB-12plusGOB-
17 [43].
These organisms are generally resistant to the conven-
tionalchemotherapeuticagentsusedinthetreatmentofneo-
natal meningitis, such as ampicillin, gentamicin, kanamycin,
and chloramphenicol [32, 44]. Diﬀerent resistance patterns
have been reported in diﬀerent outbreaks worldwide. Table 1
shows the susceptibilities of the strains of C. meningosep-
ticumisolatedduringtheoutbreaksreportedintheliterature.
8. Treatment
The appropriate choice of antimicrobial agents eﬀective for
the treatment of chryseobacterial infections is quite dif-ﬁcult
to make. Chryseobacterium spp. are resistant to most anti-
biotics and the use of inactive drugs as empirical therapy
may contribute to the poor outcome in many infections.
In addition, MIC breakpoints have not been established by
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Table 1: The susceptibilities of the strains of C. meningosepticum.
Resistance/susceptibility
References Aminoglycosides Beta-lactams Glycopeptides Quinolones
Hazuka et al. 1977 [15]N A R R N A
Thong et al. 1981 [14]R R N A N A
Di Pentima et al. 1998 [33]I R R R S
Chiu et al. 2000 [7]RR N A I R
Hoque et al. 2001 [9]R RR / S R
G¨ ung¨ or et al. 2003 [11]R R S S
Ceyhan et al. 2008 [16]R R S S
Maraki et al. 2009 [22]I R R N A N A
Hsu et al. 2010 [34]R R N A S
R: resistant, IR: intermediately resistant, S: susceptible, NA: data not available.
(NCCLS) for Chryseobacteria [23]. Antimicrobial suscepti-
bility data on Chryseobacterium spp. remain very limited,
since this pathogen has been rarely isolated from clinical
specimens. In addition, results of susceptibility testing vary
when diﬀerent methods are used. Results from disk diﬀusion
methods may not be reliable, so broth reference quality
microdilution tests should be performed when possible. The
E-test has also been suggested as a possible alternative for
testing certain antibiotics [5].
Chryseobacterium organisms produce β-lactamases and
are resistant to most β-lactam drugs, including the car-
bapenemsandaztreonam.Cefepimehaspooractivityagainst
C. meningosepticum. These organisms have an unusual
pattern of antibiotic sensitivity, being generally resistant to
thecon-ventional chemotherapeutic agentsused in the treat-
ment of neonatal meningitis, such as ampicillin, gentamicin,
kana-mycin, and chloramphenicol [30, 44].
Hoque et al. [9] reported a strain of multiresistant
C. meningosepticum isolated from eight neonates on a
neonatal intensive care unit from September 1994 to May
1996. The strain was resistant to ampicillin, ceftazidime,
imipenem, gentamicin,ciproﬂoxacin, andtrimethoprim sul-
famethoxazole, susceptible to piperacillin and amikacin, and
had varia-ble susceptibility to rifampicin and vancomycin.
G¨ ung¨ or et al. [11] reported that although all of their
isolates in the outbreak were susceptible to ciproﬂoxacin in
vitro, three patients did not respond to ciproﬂoxacin thera-
py given for 6 or 7 days. They switched the therapy to vanco-
mycin and rifampin, and all three patients survived with one
having a complication (hydrocephalus).
According to the results of the SENTRY Antimicrobial
Surveillance Program, Chryseobacterium spp. are known to
exhibitresistancetoaminoglycosides,tetracyclines,chloram-
phenicol, erythromycin, clindamycin, and teicoplanin [6, 45,
46]. However, some ﬂuoroquinolones have shown favorable
results [47, 48]. Sparﬂoxacin, clinaﬂoxacin, and levoﬂoxacin
are somewhat more active than ciproﬂoxacin [49]. Minocy-
cline has also shown good in vitro activity, while suscep-
tibility to doxycycline and trimethoprim sulfamethoxazole
appears variable. Rifampin is usually active in vitro and has
beenusedaspartofacombinationtherapytoclearpersistent
infection [50]. Vancomycin alone or in combination with
other agents, including rifampin, has been successful in
the treatment of meningitis in infants [51]. However, the
usefulness of vancomycin against Chryseobacterium spp. in-
fections has more recently been questioned [45, 47]. It was
reported that vancomycin was inactive in vitro (MIC of 16 to
more than 64μg/mL).
In our experience [18], although all of our isolates re-
mained susceptible to vancomycin, rifampicin, and linezolid
during the outbreak, resistance to imipenem and amikacin
was increased in the second and third clusters. This may be
due to an inducible resistance against these antibiotics. The
possibility of this type of resistance should be considered
when choosing an antibiotic regimen to treat C. meningosep-
ticum infection. Four of our 13 cases (1 in the second clus-
ter and 3 in the third cluster) died despite antibacterial
treatment, which had appeared to be eﬀective in sensitivity
testing. This may be due to the neonates’ prematurity and
severe disease and also may represent a diﬀerence of in vitro
activity.
Thus, there is no optimal regimen for the treatment of
Chryseobacterium spp. ˙ Infections, and antimicrobial therapy
should be based on MIC results from properly performed
susceptibility tests.
9. Prevention
Clinical studies demonstrate the importance of rapid insti-
gation of epidemiological investigation, whilst also ensuring
that fundamental infection control procedures are in place
during an outbreak and to prevent an outbreak. It is worth-
while for the infection control team to ensure that the hos-
pital water tanks are inspected and chlorinated yearly and
any necessary repair work carried out. We could not ﬁnd any
study for vaccine development in the literature.
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